IO Biotech, Inc. (IOBT)
(Delayed Data from NSDQ)
$1.38 USD
-0.02 (-1.43%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.36 -0.02 (-1.45%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IOBT 1.38 -0.02(-1.43%)
Will IOBT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IOBT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IOBT
IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IOBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IOBT
Optimistic Buy Rating for IO Biotech Amidst Promising Clinical Trial Progress and Accelerated PFS Data Timeline
IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024
Analysts Are Bullish on These Healthcare Stocks: IO Biotech (IOBT), Iterum Therapeutics (ITRM)
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech reports Q1 EPS (30c), consensus (36c)